Introduction {#sec1-1}
============

International drug regulatory agencies demand requirement of *in vivo* mammalian genotoxicity studies, for any substance that is intended for human use to achieve the protection and safety for humans, for registration and authorization as therapeutic agents.\[[@ref1][@ref2]\]

Analyzing genotoxicity of any substance, researchers study for DNA damage in cells treated with the toxic substrates. DNA damage by this toxic substrate can be manifested as single or double strand breaks, depletion of excision repair, cross-linking, alkali-labile sites, point mutations, structural and numerical chromosomal aberrations (CA). This damage can be observed either in somatic cells or germs cells to be transferred on to future generation.\[[@ref3]\]

*Silybum marianum* L (milk thistle), is a herbaceous plant that belongs to the family "Asteraceae," indigenous to North Africa and the Mediterranean and grows in the wild of Europe, Americas and Australia.\[[@ref4]\] The fruits are small (6--8 mm) long flat, dark brown, hard, smooth, and shiny, containing 1.5%--3% silymarin composed of an isomeric mixture of flavonolignans compromising of dihydroflavonol, taxifolin (TXF) and the flavanolignans, silychristin (SCN), silybinin (SBN), silydianin (SDN), and isosilybinin (ISBN).\[[@ref5]\]

Silymarin, prepared from milk thistle, has been extensively reported to have a range of medicinal values. It is found to reduce biliary cholesterol, hepatic damage, intervene with cancer, treats liver, spleen and gallbladder disorders, and acts as an anti-inflammatory and anti-diabetic agent. It also lowers glucose and lipid levels in diabetics and its medicinal value in managing hepatic disorders was reported.\[[@ref6]\] The drug is available worldwide in the form tablets or capsules under different commercial names in proprietary blend of concentrated extracts, containing various concentration of silymarin ranging mainly from 140 mg (CAPI Co, Cairo, Egypt) to 1000 mg (Pure Formulas Co., FL, USA).

As such, silymarin is known as a safe herbal product,\[[@ref7]\] and to date, there is no documented adverse side effects, or dangerous interactions have been noted; however, it is not strictly controlled. The United States Food and Drug Administration has not been able to regulate silymarin commercial products as there is no assurance of strength and/or purity and the activity may vary.\[[@ref8]\] Therefore, there is a need to prepare a pure silymarin product, and apply reliable assay systems for detecting whether silymarin is a potential mutagen; carcinogen; and/or clastogen. This work aimed at testing silymarin from the seeds of milk thistle *S. marianum* for possible clastogenic and anticlastogenic properties *in vivo* for subacute period to validate its use as a medicinal substance available worldwide.

Materials and Methods {#sec1-2}
=====================

Chemicals and reagents {#sec2-1}
----------------------

Cyclophosphamide, Colcemid, bromodeoxyuridine (BrdU) tablets Giemsa dye, standard silymarin flavonolignans (S0292), and reagents (methanol and acetic acid) were purchased from Sigma-Aldrich Co, USA.

Milk thistle plant materials {#sec2-2}
----------------------------

Seeds of milk thistle were collected between July and August, from the flower heads of the plant, grown on the rocky slopes of the middle of Sarawat mountains range known as Sarat Albaha region that rises up to 2800 meters in South Western Saudi Arabia. The sample was identified by Prof. Naser Abdulla Awad Ali of Pharmacognosy Department, College of Clinical Pharmacy, Albaha University; voucher specimen (A530) is stored in the herbarium of Pharmacognosy laboratory. Dried seed (150 g) were grounded with a household grinder until the average size of particles was \< 0.5 mm, identified with microscopy and were extracted with 80% v/v ethanol (3 L) by 2 weeks\' cold percolation. The alcoholic extract was subjected for drying under reduced pressure, and then, it was fractioned into ethyl acetate soluble portion.\[[@ref9]\] The extract was subsequently evaporated in vacuo to yield 16.1 g dark brown viscous mass, representing around 6.5% of dried seed powder. Ethyl acetate fraction is used because to have defatted product.

High-performance liquid chromatography analysis and quantification of extract {#sec2-3}
-----------------------------------------------------------------------------

Quantitative analysis of flavonolignan compounds present in silymarin was carried out using high-performance liquid chromatography (HPLC), essentially as described by Wallace et al. 2003.\[[@ref10]\] The determination of flavonolignan compounds in methanolic solution of silymarin extract samples (1.2 mg/mL) by HPLC was carried out using a Perkin Elmer series 200 (USA) with a PE-1050 pump and 7125 injector model with a 500 μL final volume loop. PE-1040M photodiode-array was the detection system. The column was a C18 (15 cm × 4.6 mm Internal Diameter, Perkin, USA). The sample injection volume was 50 μL. Methanol: Water (50:50 v/v) was used as mobile phase and the elution was done successively with various ratio of petroleum ether: Chloroform (9:1, 8:2, 1:1 v/v) and ratio of chloroform: Methanol (99:1 v/v) at 1 mL/min of flow-rate. The column was maintained at 45°C. Detection was done at 288 nm. To identify flavonolignan compounds in the sample, the standard Silymarin solution was run together with the sample. Peak-area ratios and internal standard method were used for calculations. The sample was analyzed in triplicates and the results reported as means.

Reference solution {#sec2-4}
------------------

Dilutions of the filtered methanolic standard stock solution of Silymarin (Sigma-Aldrich Co., USA), using Whatmann No. 42 filter paper, were prepared to establish a calibration curve. Overlay absorption spectra at 288 nm of concentrations of 4.0, 6.0, 8.0, 10.0, 12.0, 14.0, and 16.0 μg/mL of silymarin were recorded.

Animals {#sec2-5}
-------

Male mice, *Mus musculus*, aged 9--12 weeks with body weight (BW) 40--50 g were obtained from NAMRU-3, Cairo, Egypt. The animals were adapted to standard laboratory conditions in wire cages for 2 weeks under room temperature of 22°C and exposed to daily photoperiod of light (14 h) followed by dark (10 h). Animals were fed with standard oval pellets, (LabDiet^®^, St. Louis, MO 63144, USA). All experimental steps were conducted according to the international guidelines (Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, U.S.A.; National Academy Press: Washington D. C., 1996), including the care and handling, feeding, scarification of the animals and approved by Institutional Animal Ethics Committee (IAEC/352/233/2015).

Treatment protocol {#sec2-6}
------------------

Average daily recommended dose of silymarin for an adult human (65 kg) was estimated at 250 mg. Minimum daily dose of silymarin administered per mouse was calculated as (Daily silymarin dose per mouse = recommended human dose/average adult human BW \[gm\] X mouse average BW \[gm\]), i.e., 250/65,000 × 45 = 0.173 administered in daily doses of 0.173 mg/day for 21 successive days; giving a total dose of 3.65 mg (rounded to 4 mg); equivalent to approximately 4 mg/kg BW. Tested doses of silymarin were chosen at lesser and \>4 mg/kg BW. In preparation for feeding, mice were held as comfortable and relax as possible. Silymarin was administered orally using appropriate size disposable flexible sterile plastic feeding tubes Model FTP-22-25, 22 ga × 25 mm (1.2 mm diameter) with soft rounded tip (Instech, PA, USA). Mice were divided into groups of five animals each as recommended by ICH guidelines,\[[@ref11]\] corresponding to four treatments group with silymarin alone, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 20 mg/kg BW, four treatment groups with silymarin at 2 mg/kg, 4 mg/kg, 8 mg/kg, and 20 mg/kg BW, combined with the positive control (PC) cyclophosphamide (Indoxan) at 25 mg/kg BW, each group of positive and negative control.\[[@ref12]\] Animals of the negative control group received equivalent amounts of deionized water. Each animal was injected with 0.1 mL colcemid (20 mg), 21 h after applying the last dose of treatment. Animals were decapitated 24 h after the last dose, except for the analysis of primary spermatocytes (PS), where animals were decapitated 10 days after the last dose.

Harvesting of bone marrow {#sec2-7}
-------------------------

Animals were sacrificed and cervical dislocation technique was applied to remove both animal femurs, extraneous tissues and bone tips were discarded to allow a 26-gauge syringe needle to be inserted to flush out the femoral contents with phosphate buffered saline (pH 7.0). Cell suspension around 8 mL was microfuged at 1000 rpm (5 min), and cell pellet was recovered. The pellet was resuspended in 8 mL hypotonic solution of potassium chloride (0.075 M), and allowed to stand for 12 min before recentrifugation. The recovered cell pellet was fixed with a fixative solution (3 unit of methanol: 1 unit of glacial acetic acid v/v) for 10 min. The fixation process was repeated with each pellet obtained, resuspended in 5 mL fresh fixative solution and kept at 4°C overnight till examined. Furthermore, bone marrow smears were made according to Liju et al.\[[@ref13]\] From a feet distance, 2--3 drops of cells suspended in the fixative solution were dropped onto a glass side. Additional drops were added until cell density was dense enough. Slides were kept away from light until stained. Cells were spread, air-dried, and stained for 5 min with 10% Giemsa (pH 6.8).

Determination of bone marrow cell mitotic index {#sec2-8}
-----------------------------------------------

Bone marrow cell proliferation rate was estimated by calculating the mitotic index (MI) of stained cell smears, examined microscopically. The estimation of MI was based on at least 1000 cells using the equation (MI = No dividing cell/Total no. examined cells × 100).

Chromosomal aberrations in bone marrow cells {#sec2-9}
--------------------------------------------

Approximately 200 metaphase Giemsa-stained bone marrow cells/dose/animals were microscopically examined for CA, such as stickiness, gaps, fragments, robertsonian centric fusions, and polyploidy, and compared with the control groups.

Analysis of micronucleated polychromatic erythrocytes in the bone marrow cells {#sec2-10}
------------------------------------------------------------------------------

The frequency and relative size of micronucleus micronucleated polychromatic erythrocytes (MPE) were estimated from 300 cells using a method described by Yaduvanshi et al.,\[[@ref14]\] and the analysis of data was performed according to Hart and Engberg-Pedersen.\[[@ref15]\]

Analysis of primary spermatocytes {#sec2-11}
---------------------------------

The spermatogenic cells were mechanically obtained from the mice testes using the procedure described by Adler.\[[@ref16]\] The fusion efficiency was increased by suspending cells in PBS saline solution, and applying 0.1 mg/mg Pronase E solution for 5 min at 30°C. The biggest cells with 18--20 μm in diameter in size with distinct nuclear membrane in the pachytene to diplotene stages of the meiotic prophase were investigated for CA.

Analysis of bone marrow for sister chromatid exchange {#sec2-12}
-----------------------------------------------------

BrdU tablets were compressed using pellet press (Parr Instrument Company, Moline, ILLinois, USA) equipped with punch of 0.178" diameter as described by Allen et al.\[[@ref17][@ref18]\] Portions of 200 mg mounting powder were mixed with the BrdU dye, and firmly pressed to maintain consistent compaction, hence dissolution rate among tablets. Tablets were kept in a freezer until used. Animals were anesthetized for about 2 min in a jar containing ether and restrained on their back with ether-wet tissue placed on the nose for a prolonged anesthetic effect. Approximately 1 cm subcutaneous incision was made with a clean scissor along the lower lateral region after been swapped with alcohol, and a deeper subcutaneous pocket was created using forceps, after inserting a tablet the wound was sealed using 2--3 out clip sutures.

Silymarin treatments for sister chromatid exchange (SCE) analysis were done 8 h after BrdU tablet insertion. At 19 h after BrdU tablet insertion, each animal was injected with 0.1 mL Colcemid (20 mg) intravenously, in the tail vain. Slides were stained for 10 min in the dark\[[@ref19]\] using 50 μ/mL Hoechst dye 33258, prepared in distilled water at pH 7. The preparation was rinsed in distilled water before adding a layer of Mcilvaine\'s buffer (18 mL of citric acid \[1.92%\] added to 82 mL of disodium phosphate \[2%\] and adjusted to pH 7). A coverslip was placed on each preparation, and slides were placed at 50°C warmed plate and exposed from a distance of about 2" to light intensity at 400 nm, for 20 min. Slides received a distilled water rinse before immersion into 10% Giemsa dye, then rinsed again in distilled water, and air-dried before examined by a light microscope. At least, 50 cells per animal was analyzed. Finally, cells were examined for mitotic spread for SCE under objective magnification of 25 X, and cell examination was carried out under objective magnification of 100 X. The frequency of SCE was scored from taken photographs of microscope fields of second division cells. Each interstitial exchange of chromatid segment was counted as two incidents of SCE.

Statistical analysis {#sec2-13}
--------------------

The statistical program SPSS® (2005) version 14.0 (SPSS Inc., Chicago, Illinois, USA) was used for data analysis. Data were expressed as percentage and mean ± standard error *F*-test and the least significant difference test were used for the analysis of variance among treatments at *P* ≤ 0.05. Data were subjected to Duncan\'s multiple range tests for the chromosomal abnormalities and SCEs studies.

Results {#sec1-3}
=======

Silymarin was successfully extracted from the seeds of milk thistle. The ethyl acetate extract from 250 g dried seed powder yielded 25.1 g dark brown viscous mass representing around 10.05%. The chromatographic data of methanolic solution of silymarin sample and silymarin standard are presented in [Figure 1](#F1){ref-type="fig"}. The chromatograms depict six principal peaks, each one represents individual flavonolignan component in the Silymarin samples. The peaks for TXF, SCN, SDN, SBN A, SBN B, and ISBN appeared at retention times of 3.6, 4.4, 4.6, 9.1, 9.7, and 10.7 min, respectively. In terms of the quantity, the total silymarin contents in dry seeds of plants were 21.66 μg/g (i.e., 2.2%), representing six silymarin flavonolignan constituents.

![(a) High-performance liquid chromatography chromatogram (288 nm) of silymarin solution prepared by dissolving the standardized silymarin in methanol. Peaks: taxifolin; silychristin; silydianin; silybinin A; silybinin B; isosilybinin. (b) The chromatogram of silymarin detected at 288 nm from seeds of Milk thistle *Silybum marianum* (l) extract; (chromatographic conditions---see experimental part)](IJPharm-50-108-g001){#F1}

The results illustrating the different types of aberrations induced by cyclophosphamide as a clastogenic are shown in [Figure 2](#F2){ref-type="fig"}. The data \[[Table 1](#T1){ref-type="table"}\] show that the PC cyclophosphamide, at 25 mg/kg BW, resulted in exactly 50% reduction in the MI as compared to the negative control (8.2%). The MI increased in response to the treatments with silymarin at 2, 4, 8, and 20 mg/kg BW giving rise to 10.3%, 12.7%, 16.2%, and 16.8%, respectively. As compared to the negative control, the result gave evidence that all treatments with silymarin induced significant (*P* ≤ 0.05) increase in mitotic activity, and at 8 mg/kg and 20 mg/kg BW, silymarin achieved a 2-fold increase in the mitotic activity of bone marrow cells. It is obvious from [Table 1](#T1){ref-type="table"} that the mitotic activity obtained after treatments with silymarin in combination with the PC, although was lower than that obtained after treatment with the silymarin alone, it was either equal to or even higher than the negative control, giving further evidence that silymarin counters the effect of cyclophosphamide.

![Photomicrograph illustrating the analysis of metaphase showing aberrations. (a) stickiness "S" and chromosome deletion; (b) chromosome deletion; (c) micronucleated polychromatic erythrocytes micronucleated polychromatic erythrocytes; (d) diakinesis stage showing robertsonian centric fusion after treatment with the positive mutagenic agent cyclophosphamide](IJPharm-50-108-g002){#F2}

###### 

Effect of silymarin on mitotic activity as indicated by mitotic index of mice bone marrow cells

![](IJPharm-50-108-g003)

The CA results are summarized in [Table 2](#T2){ref-type="table"}. It was observed that there is no increase in CA following all silymarin treatments. However, treatment with the PC cyclophosphamide resulted in a significant increase (*P* ≤ 0.05) in the CA of different types; stickiness was the main aberrations. Treatment with silymarin combined with cyclophosphamide revealed that the levels of silymarin used had a positive effect on decreasing CA.

###### 

Effect of silymarin alone and in combination with the positive control cyclophosphamide on chromosomal abnormalities in mice bone marrow cells

![](IJPharm-50-108-g004)

It clearly showed that silymarin is able to decrease the MPE significantly (*P* ≤ 0.05) \[[Table 3](#T3){ref-type="table"}\]. Therefore, it designates that it plays an important role as anticlastogenic agent. PC was found to have clastogenic effect and silymarin proved to have anticlastogenic activity. The analysis of PS showed that treatment with the different doses of silymarin significantly (*P* ≤ 0.05) reduced different types of aberrations at diakinesis stage as compared to the PC as outlined in [Table 4](#T4){ref-type="table"}. The effect of silymarin on *in vivo* activation of SCEs are summarized in [Table 5](#T5){ref-type="table"} that shows the average of SCEs obtained after treatment with the different doses of silymarin as compared to the negative and PC groups. It is observed that silymarin, is not only a negative inducer of SCEs, i.e., a negative inducer of primary DNA damage, but it also plays a role in repairing primary DNA damage. Moreover, we performed Duncan\'s multiple range test as presented in [Table 6](#T6){ref-type="table"}, indicating that all tested doses were significantly (*P* ≤ 0.05) different than the PC. Comparing the negative control means SCEs and that after the treatment with 20 mg/kg BW, significantly decreased (*P* ≤ 0.05) the frequency of SCEs to almost the third of that occurred in the negative control, giving evidence that silymarin has a specific capability to repair DNA lesion.

###### 

Micronucleated polychromatic erythrocytes in mice bone marrow after treatment with silymarin

![](IJPharm-50-108-g005)

###### 

Analysis of diakinesis stage after treatment with silymarin

![](IJPharm-50-108-g006)

###### 

Effect of silymarin on the *in vivo* induction of sister chromatid exchanges in mice bone marrow cells

![](IJPharm-50-108-g007)

###### 

Duncan's multiple range test for mean differences (at *P*=0.05) of sister chromatid exchanges

![](IJPharm-50-108-g008)

Discussion {#sec1-4}
==========

Previously silybin, SCN, SDN, isosilybin and other organic polymer fraction was identified in silymarin extract.\[[@ref4][@ref20]\] As per Organisation for Economic Co-operation and Development (OECD) guidelines, acute genotoxic testing is carried out up to maximum tolerated dose whereas subacute or chronic testing can be carried out with repeated small doses. Aneuploidy such as potent spindle poisons caused by many compounds that are observed within a narrow range of doses proceeding toxic doses, in *in vivo* micronucleus assays in bone marrow or blood samples.\[[@ref11]\] Furthermore, *in vivo* studies takes in consideration of metabolite of testing compounds which can give rise to genotoxicity. Our study is subacute period of 21 days of treatment, aimed at detecting complete genotoxicity.

It is recommended for mutagenicity testing to include negative and PC groups. As per Preston et al., PCs gives test to test and animal to animal variations, and to validate the sensitivity of a particular test.\[[@ref21]\] However, cyclophosphamide is a clastogenic inducer in many animal species and has been suggested in cytogenetic studies.\[[@ref22][@ref23]\] Bone marrow cells are studied for any CA test, and it is widely used for regulatory submissions.\[[@ref11]\] The total aberrant metaphases ranged from 11% to 26%, with stickiness at highest frequencies, and the PC induced the highest frequency in stickiness, perhaps due to an alteration in the net charge of chromosomal proteins histones and acidic proteins or DNA itself.\[[@ref24]\] As per the OECD guidelines, test compound passes when none of the treatment groups shows statistically significant increase in the frequency of cells with structural CA (excluding gaps) compared with the negative control.\[[@ref25]\] Our results shown in [Table 2](#T2){ref-type="table"}, followed these criteria.

Furthermore, micronucleus test (MPE) is one of the reliable and most successful assays for screening potential genotoxic compounds.\[[@ref26]\] Our data reveal that there was a decrease in MPE. Therefore, it designates that silymarin plays an important role as anticlastogenic agent. PC was found to have clastogenic effect and silymarin proved to have anticlastogenic activity. Similar results have been reported by Kaleeswaran et al. and Zhao and Lifor acute treatment period\[[@ref27][@ref28]\] but our data support for subacute period of 21 days. These data demonstrate that silymarin does not possess any genotoxic properties.

In germ cells, heritable gene mutations, numerical and structural chromosome aberrations are induced by germ cell mutagens; because of germ cell mutations genetic, phenotypic changes without signs of illness, or fertility decrease, or embryonic or perinatal death, almost congenital malformations or genetic diseases with particular health impairment are observed in future generations.\[[@ref29]\] Study of micronuclei and other nuclear anomalies in tissues rather than bone marrow can be helpful for screening and quantifying anomalies in germinal cell.\[[@ref30]\] Our data of analysis of PS data further supported that silymarin plays a role as an anticlastogenic agent in germinal cell of mice. SCEs are a process of both DNA strands breaks, followed by an exchange of whole DNA duplexes. This process occurs during S phase and is caused by mutagens by forming DNA adducts or interfering with DNA replication. The initiation of SCEs is correlated with recombinational repair and point mutations induction, amplification of gene and cytotoxicity. In laboratory toxicology testings, SCE performed with nonradiolabel detection methods considered as genetic markers for identifying potential genotoxins/mutagens. SCE for normal distribution per mitosis is 4--5 SCE per chromosome pair, but 14--100 exchanges are not normal and considered as danger to the organism.\[[@ref31]\] Silymarin treatment has shown normal SCE distribution; and furthermore, it reduced SCE giving evidence that silymarin has a specific capability to repair DNA lesion.

Conclusion {#sec1-5}
==========

Our results substantiate evidence that silymarin has a strong anticlastogenic activity on mice genome in somatic and germ cells studies demonstrated for subacute period of 21 days. It has the capability to lower the induction of SCEs, giving an evidence that it plays an important role in repairing primary DNA damage. This effect may be due to the role of silymarin as an antioxidant, and perhaps as a DNA stabilizing agent. In contrary some findings reported for clastogenic and DNA damaging effect of silymarin by comet assay, these findings are not relevant since these studies are carried out for acute pretreatment of silymarin, with a high dose of cyclophosphamide. Therefore, the use of silymarin as a drug to treat various diseases is not only safe but also have its anti-mutagenic activities warranted.
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